Sohonos: Dosage Form, Projected Sales, NCE-1 Date | Palovarotene

Sohonos

Sohonos is a daily oral capsule for patients (8 + for females, 10 + for males) with fibrodysplasia ossificans progressiva (FOP), a condition causing abnormal bone growth. It slows new bone formation by activating retinoic acid receptors.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Palovarotene
Innovator :

IPSEN BIOPHARMACEUTICALS INC
Approval Date :

16-Aug-23
NCE-1 Date :

16-Aug-27
NCE Date :

16-Aug-28
Dosage Form :

Oral Capsules
Strength :

1mg, 1.5mg, 2.5mg, 5mg and 10mg
Therapeutic Category :

Antiossification
Revenue ($M) :

23

Year-wise Projected Sales ($M) :

2025 :

22
2026 :

25
2027 :

30
2028 :

36
2029 :

38
2030 :

43
2031 :

48

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Sohonos

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?